The present work aimed at studying the value of survivin andFADD expression as potential prognostic markers in carcinoma of thebreast, which can stratify breast cancer patients into different risk groupsmore accurately than can be achieved with current clinicopathologicclassification methods. Hence, low-risk patients can be sparedunnecessary treatment, avoiding side effects and reducing the cost oftreatment. Moreover, high-risk patients could be rapidly identified andoffered treatment modalities customized (more aggressive) to individualpatients.